Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. - Wikidata - awgldk - TriplyDB

Clinical outcomes of progressive supranuclear palsy and multiple system atrophy.

Clinical outcomes of progressive supranuclear palsy and multiple system atrophy.

http://www.wikidata.org/entity/Q34767058

about

Impact of Aspiration Pneumonia on the Clinical Course of Progressive Supranuclear Palsy: A Retrospective Cohort Study Clinical Approach to Progressive Supranuclear Palsy Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism Potential Interactions between the Autonomic Nervous System and Higher Level Functions in Neurological and Neuropsychiatric Conditions Glia and alpha-synuclein in neurodegeneration: A complex interaction Parkinsonian syndromes Differentiation of progressive supranuclear palsy: clinical, imaging and laboratory tools.Cerebellar and parkinsonian phenotypes in multiple system atrophy: similarities, differences and survival.Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy.Clinical features and disability milestones in multiple system atrophy and progressive supranuclear palsy.Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates.FDG PET in the Evaluation of Parkinson's Disease.Multiple system atrophy: prognostic indicators of survival.Multiple system atrophy as emerging template for accelerated drug discovery in α-synucleinopathies The neuropathology, pathophysiology and genetics of multiple system atrophy.Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group.FAS-dependent cell death in α-synuclein transgenic oligodendrocyte models of multiple system atrophy A longitudinal study of motor, oculomotor and cognitive function in progressive supranuclear palsy Network correlates of disease severity in multiple system atrophy.The role of autonomic testing in the differentiation of Parkinson's disease from multiple system atrophy.Urinary Dysfunction in Progressive Supranuclear Palsy Compared with Other Parkinsonian Disorders.Gene expression in the Parkinson's disease brain.Models of multiple system atrophy The natural history of multiple system atrophy: a prospective European cohort study Clinical features and autonomic testing predict survival in multiple system atrophy.Prodegenerative IκBα expression in oligodendroglial α-synuclein models of multiple system atrophy.What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)?Survival of Korean patients with multiple system atrophy.Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts.Neuropathology underlying clinical variability in patients with synucleinopathies.The potential prognostic role of cardiovascular autonomic failure in α-synucleinopathies.New horizons in the pathogenesis, assessment and management of movement disorders.The role of glia in α-synucleinopathies.The clinical approach to autonomic failure in neurological disorders.Neuropathology of multiple system atrophy: new thoughts about pathogenesis.A short clinical history of multiple system atrophy.Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Disease.New insights into orthostatic hypotension in multiple system atrophy: a European multicentre cohort study.Multiple system atrophy: insights into a rare and debilitating movement disorder.Cost-of-illness in multiple system atrophy and progressive supranuclear palsy.

P2860

Q21131719-CAEFB28A-D71F-4569-B8B5-553AD7DD5305 Q26772944-AF12C783-FFF1-42DB-929F-FE67EC506C25 Q26782028-FE1F7D8A-EF82-4028-9561-2FD6C468924C Q26782934-F3D24876-8EB9-4650-BCEB-D74251858980 Q26851153-C55593E1-9E53-4B00-91AD-6FD3EDDD3EB4 Q27007524-9429069C-036C-453C-A16F-EA16A8FBCF41 Q30588544-681018BD-98FE-4114-9408-CDC2055AEF09 Q30714986-D4F4D034-99FA-4102-9EAB-CC51F3893720 Q33615626-CA47F40D-63A0-40BD-B0FC-97536E365A23 Q33636262-D38540BF-7FD7-41E2-8615-4470B3CC30B4 Q33805560-34A0FECB-2AE3-4CA4-B103-745878C78BF9 Q34035765-B2A184E5-B975-402D-9476-FD4B2C9696C8 Q34071142-A5651107-0880-4A37-8807-F6C1C3998DCC Q34078528-FB432202-4E58-4DA5-9DF4-DF2EFF257788 Q34231585-F7AD7A03-F648-4630-A782-87CE2709CD2D Q34245237-B4F4BABB-19B3-4889-A0B2-057C56B352C8 Q34571668-2590A168-2E0E-426E-9020-D6948908D466 Q34994716-1D416F1B-CD29-4E4A-BD95-99543CE1B4CB Q35883193-BA22D8D8-9C0D-41B2-A918-A8211CE3A56A Q35923029-FC7F6E3A-B544-4AD4-82D3-DD8D56D2A225 Q35926033-4BD4B495-7B15-40AC-8089-8D2289D31395 Q36069691-2B5E39ED-E7E3-46CA-858D-9C3DBE33AC6D Q36513407-A14900A1-C624-4150-9E87-669FB00B8026 Q36637012-1FA2BC25-14FB-4B3F-8EAD-A28B1F1A1F5D Q36824638-5A68D053-546A-4946-9831-975DBF4BAD0D Q37092530-3B9463C1-F2D9-4DDB-8F4E-5711F36BA15D Q37682763-5AE14559-F336-44BD-8AF7-31F0478C5DEC Q37834518-B2080512-5218-45CE-9A06-63D30182FFE5 Q37874476-185535BB-9DD0-4C90-A086-C240365D10F7 Q37896515-28F811BB-CBB9-42F2-B223-95B798F93A7E Q38029778-DB752862-439D-4193-8A2B-42B8EC70BBD9 Q38036239-C5FED444-A291-4C46-AC7D-069E3290ED80 Q38039880-E8FD9C6F-6FC4-455C-833D-E6281DA9E832 Q38215382-35E99D5A-8B97-46E9-B31B-5F3C21597E16 Q38258246-104C32EB-E192-4AE8-8D31-CBE700FE5ED7 Q38314149-58473DE1-9A2F-40AC-91C0-839CCD284E67 Q38373533-87033FAE-6BC2-4D9A-9B90-D9EC0400E34C Q39006423-37A3F17B-24B3-42DE-9211-815B8EA559E8 Q39183459-5464688F-125F-4342-99ED-632E31E20912 Q39762141-C66CD8AD-2DAC-4405-ADB8-C1BD6CA48910

P2860

Clinical outcomes of progressive supranuclear palsy and multiple system atrophy.

http://www.wikidata.org/entity/Q34767058

description

2008 nî lūn-bûn

@nan

2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Clinical outcomes of progressive supranuclear palsy and multiple system atrophy.

@ast

Clinical outcomes of progressive supranuclear palsy and multiple system atrophy.

@en

Clinical outcomes of progressive supranuclear palsy and multiple system atrophy.

@nl

type

label

Clinical outcomes of progressive supranuclear palsy and multiple system atrophy.

@ast

Clinical outcomes of progressive supranuclear palsy and multiple system atrophy.

@en

Clinical outcomes of progressive supranuclear palsy and multiple system atrophy.

@nl

prefLabel

Clinical outcomes of progressive supranuclear palsy and multiple system atrophy.

@ast

Clinical outcomes of progressive supranuclear palsy and multiple system atrophy.

@en

Clinical outcomes of progressive supranuclear palsy and multiple system atrophy.

@nl

P1433

Q34767058-5457F41F-9F5A-4F20-B0F4-0874A40F5E8A

P1476

Q34767058-2D31CEA3-1363-4507-8BD7-669906F9E167

P2093

Q34767058-93525629-7CCD-424A-B87D-96D107BAB2A1

Q34767058-93E363DC-081E-4738-90D4-9E872B245868

Q34767058-95CD98E8-D29F-4877-873D-93B109958FC8

Q34767058-9EBF40AC-F233-49C6-A3A7-CEC470684708

Q34767058-AEBBE311-E867-4E26-95A2-20311E0F6240

Q34767058-D77E79E0-DBEA-496B-9F7C-64560B69F837

Q34767058-FB063D56-DC4B-4895-A6EB-07E9475D88C1

P2860

Q34767058-00FB8A1E-0D22-4F22-A3BE-69B6172722D8

Q34767058-013D8874-2F63-4E17-976B-B4806BCAA043

Q34767058-08225129-BF12-449C-9B75-CAD9E4935430

Q34767058-0A78B70B-D55C-49E2-B491-1E774D32F8DD

Q34767058-13141659-3901-400A-8BDE-7448305B22B2

Q34767058-19B757CD-408A-48D1-94D5-EE7F5EE82987

Q34767058-212EAE0B-0BF1-462D-97CF-C3116C9AE4E1

Q34767058-29B83180-3635-4CDB-9E21-A3C57CF50C84

Q34767058-2EC5128C-BE02-4DB2-A9E7-FDA2DA4D0044

Q34767058-3C3D6E6B-F384-4840-AAD3-0FF21BCBCB9B

P304

Q34767058-586286FD-691A-4A6B-B789-9C9A07ACAFDD

P31

Q34767058-5B3009E4-2AF7-4065-A403-0534FD9595A8

P356

Q34767058-96EA4E9D-F560-4323-B4D9-309BA9C3CB49

P407

Q34767058-C186D690-7CE2-4BB9-B55F-71F12D42B269

P433

Q34767058-48ECEC12-9ECA-4EE6-9C4F-C2C3381F1863

P478

Q34767058-FEA8A6EA-FFA3-4094-BEA9-22F9E28140F0

P50

Q34767058-CFF7F0C3-91BD-4D25-BF9B-29F2EF7BCFF4

P577

Q34767058-41142E4E-72BB-4971-98C0-E833EABE8899

P5875

Q34767058-0B2D441B-4DB8-4479-AE84-8FE3B9EA7EB1

P698

Q34767058-012EF220-CC41-4D7A-A26C-275BFB75D1D4

P356

P1433

P1476

Clinical outcomes of progressive supranuclear palsy and multiple system atrophy.

@en

P2093

D R Williams

http://www.w3.org/2001/XMLSchema#string

J L Holton

http://www.w3.org/2001/XMLSchema#string

L A Massey

http://www.w3.org/2001/XMLSchema#string

L Silveira-Moriyama

http://www.w3.org/2001/XMLSchema#string

P A Kempster

http://www.w3.org/2001/XMLSchema#string

S S O'Sullivan

http://www.w3.org/2001/XMLSchema#string

T Revesz

http://www.w3.org/2001/XMLSchema#string

P2860

The dopaminergic response in multiple system atrophy.

Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients.

What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease?

The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service.

Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy.

Idiopathic Parkinson's disease combined with multiple system atrophy. A clinicopathological report.

Consensus statement on the diagnosis of multiple system atrophy.

Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT

Clinicopathological study of 35 cases of multiple system atrophy.

Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.

P304

1362-1372

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/BRAIN/AWN065

http://www.w3.org/2001/XMLSchema#string

P407

P433

Pt 5

http://www.w3.org/2001/XMLSchema#string

P478

131

http://www.w3.org/2001/XMLSchema#string

P50

Andrew John Lees

P577

2008-04-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5467849

http://www.w3.org/2001/XMLSchema#string

P698

18385183

http://www.w3.org/2001/XMLSchema#string